Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first ...

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

September 18, 2024 • This Shanghai bookstore, now in D.C., was revived by its owner, who hopes to create a space for open discussions in the diaspora community, where people can sit and read ...

The Food and Drug Administration approved Merck's vaccine designed to protect adults from a bacteria known as pneumococcus ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 5.6% over the past three months. But if you pay close attention, you might find that ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

Merck lowered 2024 EPS guidance down to $7.94 to $8.03, from its previous guidance of $8.53 to $8.65. The new guidance reflects the negative impact of a one-time charge of $1.3 billion or 51 cents ...

By Maggie Aime, MSN, RN Expert Contributor Dr. Aneesha Dhargalkar Expert Contributor Dr. Fatema Dawoodbhoy, MBBS, BSc Reviewed by Stephanie Hope Fact Checked by Heather Morsellino Our team thoroughly ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck (MRK) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.